Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1.Tokyo, Japan, July 10, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Taiho Pharmaceutical and sanofi-aventis have entered into a licensing agreement for TS-1, an anticancer agent developed by Taiho Pharmaceutical. Under the agreement terms announced on June 4, sanofi-aventis will receive the rights to develop and commercialize the agent worldwide except in Japan and some Asian countries. Sanofi-aventis will make an upfront payment, milestone payments for development and royalties on futures sales to Taiho Pharmaceutical. Going forward, sanofi-aventis will develop the agent under the codename of S-1 while receiving the supply from Taiho Pharmaceutical. TS-1/S-1 is an oral pyrimidine fluoride-derived anticancer agent which has been available in Japan since 1999. It is indicated for the treatment of gastric cancer gastric cancer Stomach cancer, see there , colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. , head and neck cancer, non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. and inoperable inoperable /in·op·er·a·ble/ (in-op´er-ah-b'l) not susceptible to treatment by surgery. in·op·er·a·ble adj. Unsuitable for a surgical procedure. or recurrent breast cancer. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion